GlassScriptPhysician profile
Michael Mcardle
NPI 1588924872
$4,568.50
in general payments reported to CMS, 2019-2025
24 companies · $763 in 2025
The $763 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,013 · 2020: $632 · 2024: $161 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,364.22 | 2019-2025 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $528.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $447.77 | 2019-2025 | |
| Amgen INC. | $391.75 | 2019-2025 | Repatha |
| Abiomed | $370.04 | 2019-2025 | Impella |
| Janssen Pharmaceuticals, INC | $229.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $203.69 | 2019-2025 | Farxiga, Wainua |
| Cardiovascular Systems INC. | $157.48 | 2019 | |
| Scpharmaceuticals INC. | $151.52 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $139.99 | 2019-2025 | Uptravi, Opsumit |
| Abbott Laboratories | $125.67 | 2019-2025 | Diamondback Peripheral |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.07 | 2024-2025 | Jardiance |
| Pfizer INC. | $88.71 | 2019-2025 | |
| Astellas Pharma US INC | $68.27 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $30.71 | 2024 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.86 | 2025 | |
| Novo Nordisk INC | $21.79 | 2025 | Wegovy |
| Philips North America LLC | $21.27 | 2019 | |
| Teleflex LLC | $20.05 | 2020 | |
| Chiesi USA, INC. | $19.94 | 2019 | |
| Penumbra, INC. | $17.53 | 2019 | |
| Atricure, INC. | $16.10 | 2024 | |
| Amarin Pharma, INC. | $15.76 | 2019 | |
| Heartflow, INC. | $15.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcardle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.